Roivant Provides Update on Graves’ Disease Development Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Roivant Provides Update on Graves’ Disease Development Program

Roivant Sciences (ROIV) PT Raised to $12.50 at BofA Securities

September 11, 2024 5:18 AM EDT

BofA Securities analyst Chi Fong raised the price target on Roivant Sciences (NASDAQ: ROIV) to $12.50 (from $12.00) while maintaining a Neutral rating.

The analyst comments "Roivant (ROIV) disclosed a new Ph2-ready program, mosliciguat, for interstitial lung disease (PH-ILD). We think the Ph1... More